×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Hepion's NASH trial hangs in balance amid cost-cutting, CEO exit
Fierce Biotech
Hepion Pharmaceuticals is trying to stay afloat as the biotech's CEO hits the exit and the company seeks strategic alternatives, leaving the...
5 months ago
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
InvestorPlace
Hepion Pharmaceuticals stock is falling on Monday as investors in HEPA learn of the company winding down a Phase 2b clinical trial.
1 month ago
Hepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down Trial
MarketWatch
By Stephen Nakrosis Shares of Hepion Pharmaceuticals dropped in post-market on Friday after it disclosed plans to wind down its Ascend-Nash...
1 month ago
Hepion shelves Phase II NASH trial amid shallow cash resources
Clinical Trials Arena
The future of Hepion's ASCEND-NASH study was already in the balance following cost-cutting measures last December.
1 month ago
Hepion Pharmaceuticals CEO steps down amid restructuring
NJBIZ
In addition, Edison-based Hepion said CEO and Director Robert Foster resigned from his positions for personal reasons, effective immediately.
5 months ago
Is Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) A Volatile Stock?
Yahoo Lifestyle Canada
If you own shares in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) then it's worth thinking about how it contributes to...
1 week ago
Hepion Pharmaceuticals halts NASH trial due to funding issues By Investing.com
Investing.com
Hepion Pharmaceuticals halts NASH trial due to funding issues ... EDISON, N.J. - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
1 month ago
HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024
MSN
Hepion Pharmaceuticals just reported results for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This Company You've Never...
1 week ago
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday? - Hepion Pharma
Benzinga
Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic...
1 month ago
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase ...
GlobeNewswire
Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in...
6 months ago